KLK-targeted Therapies for Prostate Cancer

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Prostate cancer, particularly metastatic castration-resistant disease, requires novel therapeutic strategies.
• Proteolytic enzymes, including prostate-specific antigen (PSA) and KLK2, play significant roles in prostate cancer progression.
• The precise functions of KLKs in prostate cancer, including potential pro- and anti-cancer activities, are not fully understood.

Purpose of the Study:

• To review the current status of kallikrein-related peptidases (KLKs) as therapeutic targets for prostate cancer.
• To highlight the potential of modulating KLK proteolytic activity for cancer treatment.
• To discuss the challenges and future directions in targeting KLKs for prostate cancer therapy.

Main Methods:

• Literature review of studies on KLKs in prostate cancer.
• Analysis of the proposed roles of PSA and KLK2 in tumor development and angiogenesis.
• Examination of therapeutic strategies targeting KLKs, including prodrugs and vaccines.

Main Results:

• KLKs, particularly PSA and KLK2, are attractive targets due to their roles in tumor progression and prostate-specific expression.
• Early clinical results of PSA/KLK2-targeted prodrugs and vaccines are encouraging.
• Limited molecules currently exist that selectively modulate KLK activity for therapeutic use.

Conclusions:

• KLKs represent a promising area for novel prostate cancer therapeutics.
• Further research is needed to fully understand and exploit the therapeutic potential of KLKs.
• Targeting KLK proteolytic activity offers a potential strategy to control prostate cancer growth and metastasis.